Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-09-05
1991-12-03
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548147, A61K 31415, C07D23502
Patent
active
050701002
ABSTRACT:
Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome. A particularly preferred class of compounds comprise difluoro-dialkoxy substituted spiro-(9H-fluorene-9,4'-imidazolidine)-2,40 ,5-diones.
REFERENCES:
patent: 3138608 (1964-06-01), Davis
patent: 3153050 (1964-10-01), Davis
patent: 4127665 (1978-11-01), Sarges et al.
patent: 4436745 (1984-03-01), York
patent: 4438272 (1984-03-01), York
patent: 4537892 (1985-08-01), York
Winstead et al, Journal of Medicinal Chemistry, vol. 19, No. 2, pp. 279-286, 1976.
Pan et al, Journal of Medicinal Chemistry, vol. 10, No. 1, pp. 957-959, 1967.
Pan et al, Journal of Medicinal Chemistry, vol. 7, pp. 31-38, 1964.
Alcon Laboratories Inc.
Arno James A.
Brown Gregg C.
Ford John M.
Price Robert L.
LandOfFree
Spiro-tricyclicaromatic succinimide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiro-tricyclicaromatic succinimide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiro-tricyclicaromatic succinimide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1697232